KR870002848A - 항응고물질, 그 제조방법 및 이물질을 유효 성분으로 포함하는 항응고제 - Google Patents

항응고물질, 그 제조방법 및 이물질을 유효 성분으로 포함하는 항응고제 Download PDF

Info

Publication number
KR870002848A
KR870002848A KR1019860008120A KR860008120A KR870002848A KR 870002848 A KR870002848 A KR 870002848A KR 1019860008120 A KR1019860008120 A KR 1019860008120A KR 860008120 A KR860008120 A KR 860008120A KR 870002848 A KR870002848 A KR 870002848A
Authority
KR
South Korea
Prior art keywords
prolong
anticoagulant
minutes
stable
isoelectric point
Prior art date
Application number
KR1019860008120A
Other languages
English (en)
Other versions
KR940003751B1 (ko
Inventor
마사히로 마키
히데오 타니
Original Assignee
미와 타카야수
코와 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16705389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR870002848(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 미와 타카야수, 코와 가부시키가이샤 filed Critical 미와 타카야수
Publication of KR870002848A publication Critical patent/KR870002848A/ko
Application granted granted Critical
Publication of KR940003751B1 publication Critical patent/KR940003751B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C1/00—Photosensitive materials
    • G03C1/005—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein
    • G03C1/04—Silver halide emulsions; Preparation thereof; Physical treatment thereof; Incorporation of additives therein with macromolecular additives; with layer-forming substances
    • G03C1/047—Proteins, e.g. gelatine derivatives; Hydrolysis or extraction products of proteins
    • G03C2001/0471—Isoelectric point of gelatine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/842—Skin; hair; nails; sebaceous glands; cerumen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/851—Placenta; amniotic fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

항응고물질, 그 제조방법 및 이물질을 유효 성분으로 포함하는 항응고제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. (1) 환원 상태에서 SDS-폴리아크릴 아미드 겔 전기 영동에 의해 측정된 분자량이 34,000±2,000이고,
    (2) 양성 전해질을 사용하는 등전점 컬럼 전기 영동에 의해 측정된 등전점이 4.7±0.1이고,
    (3) 안전성에 있어서는,
    (a) 50℃에서 30분간 열처리 함으로써 불활성화되고,
    (b) 4-10의 pH에서 안정하고,
    (c) 혈장 내에서 37℃하에 30분간 안정하며,
    (4) 활성에 있어서는,
    (a) 칼슘 재침착 시간을 연장시킬 수 있고,
    (b) 프로트롬빈 시간을 연장시킬 수 있고,
    (c) 활성화된 부분 트롬보 플라스틴 시간을 연장시킬 수 있으며,
    (5) 아미노산 분석시에는, 아스파라긴산, 트레오닌, 세린, 글루타민산, 프롤린, 글리신, 알라닌, 1/2시스틴, 발린, 메티오닌, 이소로이신, 로이신, 티로신, 페닐알라닌, 히스티딘, 리신 및 아르기닌의 존재가 확인된다는 성질을 갖고 있는, 인간의 태반으로부터 유래된 항응고물질.
  2. 인간의 태반을 균질화시키고, 생성된 균등질을 원심 분리시키고, 계면활성제 및 또는 킬레이트제를 사용하여 잔류물로부터 또는 상청액 속에 들어있는 미립체 분류물로부터 항응고물질을 추출시키고, 그 물질을 추출물로부터 정제 및 분리시키는 단계들로 이루어진, 인간의 태반으로부터 유래되며, 하기 (1)∼(5)의 성질을 갖고 있는 항응고 물질의 제조방법.
    (1) 환원 상태에서 SDS-폴리아크릴 아미드 겔전기 영동에 의해 측정된 분자량이 34,000±2,000이고,
    (2)양성 전해질을 사용하는 등전점 컬럼 전지 영동에 의해 측정된 등전점이 등전점이 4.7±0.1이고,
    (3) 안전성에 있어서는,
    (a) 50℃에서 30분간 열처리함으로써 불활성화되고,
    (b) 4-10의 pH에서 안정하고,
    (c) 혈장 내에서 37℃하에 30분간 안정하며,
    (4) 활성에 있어서는,
    (a) 칼슘 재침착 시간을 연장시킬 수 있고,
    (b) 프로트롬빈 시간을 연장시킬 수 있고,
    (c) 활성화된 부분 트롬보플라스틴 시간을 연장시킬 수 있고,
    (5) 아미노산 분석시에는, 아스파라긴산, 트레오닌, 세린, 글루타민산, 프롤린, 글리신, 알라닌, 1/2시스틴, 발린, 메티오닌, 이소로이신, 로이신, 티로신, 페닐알라닌, 히스티딘, 리신 및 아르기닌의 존재가 확인된다.
  3. 인간의 태반으로부터 유래되며, 하기 (1)∼(5)의 성질을 갖고 있는 항응고물질을 유효량만큼 포함하는 항응고체,
    (1) 환원 상태에서 SDS-폴리아크릴 아미드 겔 전기 영동에 의해 측정된 분자량이 34,000±2,000이고,
    (2)양성 전해질을 사용하는 등전점 컬럼 전지 영동에 의해 측정된 등전점이 4.7±0.1이고,
    (3) 안전성에 있어서는,
    (a) 50℃에서 30분간 열처리 함으로써 불황성화되고,
    (b) 4-10의 pH에서 안정하고,
    (c) 혈장 내에서 37℃하에 30분간 안정하며,
    (4) 활성에 있어서는,
    (a) 칼슘재침착 시간을 연장시킬 수 있고,
    (b) 프로트롬빈 시간을 연장시킬 수 있고,
    (c) 활성화된 부분 트롬보플라스틴 시간을 연장시킬 수 있으며,
    (5) 아미노산 분석시에는, 아스파라긴산, 트레오닌, 세린, 글루타민산, 프롤린, 글리신, 알라닌, 1/2시스틴, 발린, 메티오닌, 이소로이신, 로이신, 티로신, 페닐알라닌, 히스티딘, 리신 및 아르기닌의 존재가 확인된다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860008120A 1985-09-30 1986-09-27 항혈액 응고물질의 제조방법 KR940003751B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP217512/1985 1985-09-30
JP217512 1985-09-30
JP21751285 1985-09-30

Publications (2)

Publication Number Publication Date
KR870002848A true KR870002848A (ko) 1987-04-13
KR940003751B1 KR940003751B1 (ko) 1994-04-30

Family

ID=16705389

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860008120A KR940003751B1 (ko) 1985-09-30 1986-09-27 항혈액 응고물질의 제조방법

Country Status (7)

Country Link
US (1) US4732891A (ko)
EP (1) EP0217341B2 (ko)
JP (1) JPH0710880B2 (ko)
KR (1) KR940003751B1 (ko)
CA (1) CA1265446A (ko)
DE (1) DE3676148D1 (ko)
ES (1) ES2001707A6 (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066788A (en) * 1984-09-21 1991-11-19 Boehringer Ingelheim International Gmbh Blood coagulation inhibiting proteins, processes for preparing them and their uses
US5264550A (en) * 1985-04-15 1993-11-23 Scios Nova Inc. Human anti-inflammatory phospholipase inhibitor protein
ATE113062T1 (de) * 1986-07-15 1994-11-15 Kowa Co Throminbindende substanz und verfahren zu ihrer herstellung.
JPH0764878B2 (ja) * 1986-10-14 1995-07-12 興和株式会社 抗血液凝固物質及びその製法
JPH08840B2 (ja) * 1986-11-14 1996-01-10 興和株式会社 抗ｐｃｉモノクローナル抗体、これを用いた抗ｐｃｉの精製法及び免疫学的測定法
DE3643182A1 (de) * 1986-12-18 1988-06-30 Behringwerke Ag Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4
US4937324A (en) * 1987-02-06 1990-06-26 Zymogenetics, Inc. Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity
JP2660514B2 (ja) * 1987-02-20 1997-10-08 興和株式会社 抗血液凝固作用を有するポリペプチド
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
DE3724726A1 (de) * 1987-07-25 1989-02-02 Behringwerke Ag Verfahren zur reinigung des plazentaren gewebeproteins pp4
DE3737237A1 (de) * 1987-11-03 1989-05-18 Behringwerke Ag Anticoagulatorisches protein pp4-x, seine herstellung und verwendung
DE3737239A1 (de) * 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
JP2660548B2 (ja) * 1988-06-15 1997-10-08 興和株式会社 膠原病疾患関連抗体検出用試薬及びこれを用いる膠原病疾患関連抗体の検出方法
US5202421A (en) * 1988-12-27 1993-04-13 Mochida Pharmaceutical Co., Ltd. Anticoagulant substance obtained from urine and process for the preparation thereof
EP0409052B1 (de) * 1989-07-15 1993-05-12 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Antikoagulanz enthaltendes Mittel
WO1992008475A1 (fr) * 1990-11-20 1992-05-29 Kowa Co., Ltd. Agent therapeutique pour la peau ou contre les maladies corneennes
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
AU5062100A (en) 1999-06-14 2001-01-02 Novo Nordisk A/S Fviia/tf activity inhibiting compounds
DE60138111D1 (de) * 2000-07-21 2009-05-07 Chemo Sero Therapeut Res Inst Verfahren zur reinigung eines kalziumionen-bindenden proteins
DE60219611T2 (de) * 2001-02-21 2007-12-27 Alavita Pharmaceuticals, Inc., Mountain View Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
WO2002067977A1 (fr) * 2001-02-26 2002-09-06 Kowa Company, Ltd. Gouttes ophtalmiques
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
US6982154B2 (en) * 2002-02-21 2006-01-03 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE636817A (ko) * 1962-08-31
US3310471A (en) * 1965-05-13 1967-03-21 Upjohn Co Placental lactogenic factor process
US3409605A (en) * 1965-06-15 1968-11-05 American Cyanamid Co Concentration and purification of growth factor-placental origin (human)
BE787961A (fr) * 1971-08-24 1973-02-26 Behringwerke Ag Procede d'isolement d'une matiere thromboplastique et medicament contenant ladite matiere
DE2640387C3 (de) * 1976-09-08 1981-01-22 Behringwerke Ag, 3550 Marburg Gewebespezifisches Protein und Verfahren zu dessen Herstellung
DE2720704C2 (de) * 1977-05-07 1986-09-25 Behringwerke Ag, 3550 Marburg Neues Glycoprotein, Verfahren zu seiner Herstellung und seine Verwendung
IT1114943B (it) * 1977-12-27 1986-02-03 Sclavo Inst Sieroterapeut Processo per la preparazione di somatomammotropina corionica umana
DE2842467A1 (de) * 1978-09-29 1980-04-10 Behringwerke Ag Neues ubiquitaeres gewebsprotein pp tief 8
DE2952792A1 (de) * 1979-12-31 1981-07-02 Behringwerke Ag, 3550 Marburg Neues protein (pp(pfeil abwaerts)15(pfeil abwaerts)) mit immunsuppressiver wirkung
DE3230996A1 (de) * 1982-08-20 1984-02-23 Behringwerke Ag, 3550 Marburg Neues protein (pp(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)3(pfeil abwaerts)), verfahren zu seiner anreicherung und gewinnung sowie seine verwendung
DE3315000A1 (de) * 1983-04-26 1984-10-31 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)4(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
JPS6019719A (ja) * 1983-07-15 1985-01-31 Asahi Chem Ind Co Ltd 抗腫瘍活性を有する蛋白質
DE3338480A1 (de) * 1983-10-22 1985-05-02 Behringwerke Ag, 3550 Marburg Neues protein pp(pfeil abwaerts)2(pfeil abwaerts)(pfeil abwaerts)0(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
JPS60152421A (ja) * 1984-01-23 1985-08-10 Sanwa Kagaku Kenkyusho:Kk ヒト胎盤性プラスミノ−ゲン活性化因子、及びそれとヒトプラスミノ−ゲン活性化阻害因子との結合物、及びそれらの製法
DE3404563A1 (de) * 1984-02-09 1985-08-14 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)9(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
EP0182929A1 (de) * 1984-11-26 1986-06-04 American Hospital Supply Corporation Koaktivator zur Aktivierung von Protein C

Also Published As

Publication number Publication date
CA1265446A (en) 1990-02-06
EP0217341A3 (en) 1988-04-06
EP0217341A2 (en) 1987-04-08
ES2001707A6 (es) 1988-06-01
JPS62174023A (ja) 1987-07-30
DE3676148D1 (de) 1991-01-24
US4732891A (en) 1988-03-22
EP0217341B2 (en) 1997-12-17
KR940003751B1 (ko) 1994-04-30
EP0217341B1 (en) 1990-12-12
JPH0710880B2 (ja) 1995-02-08

Similar Documents

Publication Publication Date Title
KR870002848A (ko) 항응고물질, 그 제조방법 및 이물질을 유효 성분으로 포함하는 항응고제
Markland et al. Purification and properties of a thrombin-like enzyme from the venom of Crotalus adamanteus (Eastern diamondback rattlesnake)
Ouyang et al. α-and β-fibrinogenases from Trimeresurus gramineus snake venom
Kato et al. Changes in prolyl endopeptidase during maturation of rat brain and hydrolysis of substance P by the purified enzyme
Andersson et al. Purification and characterization of human factor IX
Lecroisey et al. Chemical and Enzymatic Characterization of the Collagenase from the Insect Hypodeårma lineatum
Ouyang et al. Purification and properties of the thrombin-like principle of Agkistrodon acutus venom and its comparison with bovine thrombin
AR035786A2 (es) Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen
Bluard-Deconinck et al. Iron-binding fragments from the N-terminal and C-terminal regions of human lactoferrin
Angeletti Nerve growth factor from cobra venom
Herbrink et al. Further studies on the polypeptide chains of β-crystallin
Ouyang et al. Physicochemical properties of α-and β-fibrinogenases of Trimeresurus mucrosquamatus venom
Fukasawa et al. Comparison of dipeptidyl peptidase IV prepared from pig liver and kidney
Tsukahara et al. An ATP‐dependent protease and ingensin, the multicatalytic proteinase, in K562 cells
Chung Multiple molecular forms of transglutaminases in human and guinea pig
Hiestand et al. Dispholidus typus (boomslang) snake venom: purification and properties of the coagulant principle
Davis III et al. Human factor. hivin. D of the alternative complement pathway. Physicochemical characteristics and N-terminal amino acid sequence
Ole-MoiYoi et al. Structural studies of human urinary kallikrein (urokallikrein).
Xu et al. Purification and characterization of anticoagulation factors from the venom of Agkistrodon acutus
Himeno et al. The synthesis of rat liver lysosomes: III. chemical composition of microsomal and lysosomal β-glucuronidases purified from rat liver
Bajwa et al. A new method for purification of the thrombin-like enzyme from the venom of the eastern diamondback rattlesnake
Wynn Solubilization of insoluble collagens by rat liver lysosomes
Weser et al. Superoxide dismutase in baker's yeast
Dimroth Purification of the sodium transport enzyme oxaloacetate decarboxylase by affinity chromatography on avidin sepharose
Łukasiewicz et al. The plasmin inhibition by synthetic antifibrinolytic agents in relation to the type of substrate

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050310

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee